Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer
Clinical trial NCT01997333 · COMPLETED
Trial details
- NCT number
- NCT01997333
- Sponsor
- Celldex Therapeutics
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2013-11-01
- Primary completion
- 2017-11-30
- Enrollment
- 327
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.